Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Jpn J Clin Oncol ; 46(5): 482-92, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-27207993

RESUMO

OBJECTIVE: The incidence of breast cancer has progressively increased, making it the leading cause of cancer deaths in Japan. Breast cancer accounts for 20.4% of all new cancers with a reported age-standardized rate of 63.6 per 100 000 women. METHODS: The Japanese guidelines for breast cancer screening were developed based on a previously established method. The efficacies of mammography with and without clinical breast examination, clinical breast examination and ultrasonography with and without mammography were evaluated. Based on the balance of the benefits and harms, recommendations for population-based and opportunistic screenings were formulated. RESULTS: Five randomized controlled trials of mammographic screening without clinical breast examination were identified for mortality reduction from breast cancer. The overall relative risk for women aged 40-74 years was 0.75 (95% CI: 0.67-0.83). Three randomized controlled trials of mammographic screening with clinical breast examination served as eligible evidence for mortality reduction from breast cancer. The overall relative risk for women aged 40-64 years was 0.87 (95% confidence interval: 0.77-0.98). The major harms of mammographic screening were radiation exposure, false-positive cases and overdiagnosis. Although two case-control studies evaluating mortality reduction from breast cancer were found for clinical breast examination, there was no study assessing the effectiveness of ultrasonography for breast cancer screening. CONCLUSIONS: Mammographic screening without clinical breast examination for women aged 40-74 years and with clinical breast examination for women aged 40-64 years is recommended for population-based and opportunistic screenings. Clinical breast examination and ultrasonography are not recommended for population-based screening because of insufficient evidence regarding their effectiveness.


Assuntos
Neoplasias da Mama/diagnóstico , Adulto , Idoso , Povo Asiático , Neoplasias da Mama/diagnóstico por imagem , Detecção Precoce de Câncer , Reações Falso-Positivas , Feminino , Guias como Assunto , Humanos , Japão , Mamografia , Programas de Rastreamento , Pessoa de Meia-Idade , Risco , Ultrassonografia
2.
Endoscopy ; 45(1): 51-9, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23212726

RESUMO

Population-based screening for early detection and treatment of colorectal cancer (CRC) and precursor lesions, using evidence-based methods, can be effective in populations with a significant burden of the disease provided the services are of high quality. Multidisciplinary, evidence-based guidelines for quality assurance in CRC screening and diagnosis have been developed by experts in a project co-financed by the European Union. The 450-page guidelines were published in book format by the European Commission in 2010.  They include 10 chapters and over 250 recommendations, individually graded according to the strength of the recommendation and the supporting evidence. Adoption of the recommendations can improve and maintain the quality and effectiveness of an entire screening process, including identification and invitation of the target population, diagnosis and management of the disease and appropriate surveillance in people with detected lesions. To make the principles, recommendations and standards in the guidelines known to a wider professional and scientific community and to facilitate their use in the scientific literature, the original content is presented in journal format in an open-access Supplement of Endoscopy. The editors have prepared the present overview to inform readers of the comprehensive scope and content of the guidelines.


Assuntos
Neoplasias Colorretais/diagnóstico , Programas de Rastreamento/normas , Garantia da Qualidade dos Cuidados de Saúde , Detecção Precoce de Câncer , Europa (Continente) , Medicina Baseada em Evidências , Humanos
3.
Aliment Pharmacol Ther ; 15(11): 1777-85, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11683692

RESUMO

BACKGROUND: Helicobacter pylori eradication triple therapy with a combination of lansoprazole, amoxicillin and clarithromycin was approved in Japan in September 2000. AIM: To compare the cost-effectiveness of this eradication therapy with conventional histamine-2 receptor antagonist therapy in Japan. METHODS: We established two Markov models for gastric and duodenal ulcers. The model design was based on the Japanese H. pylori eradication guideline and a specialist's opinions, and the model inputs were obtained from a literature review. The models predict the direct medical costs, number of disease-free days and cost per disease-free day for 5 years. RESULTS: In the gastric ulcer model, the expected total costs of eradication and conventional therapies per patient were yen169 719 and yen390 921, respectively; the expected numbers of disease-free days were 1454 days and 1313 days, respectively. In the duodenal ulcer model, the expected total costs were yen134 786 and yen324 689, respectively; the expected numbers of disease-free days were 1503 days and 1387 days, respectively. The sensitivity analyses showed that the results of the base case analysis were robust. CONCLUSIONS: This eradication therapy is less costly and more effective than conventional therapy for the treatment of gastric and duodenal ulcers in a Japanese medical setting.


Assuntos
Amoxicilina/uso terapêutico , Antibacterianos/uso terapêutico , Antiulcerosos/uso terapêutico , Claritromicina/uso terapêutico , Custos de Cuidados de Saúde/estatística & dados numéricos , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/economia , Omeprazol/análogos & derivados , Omeprazol/uso terapêutico , Penicilinas/uso terapêutico , 2-Piridinilmetilsulfinilbenzimidazóis , Amoxicilina/administração & dosagem , Amoxicilina/economia , Antibacterianos/administração & dosagem , Antibacterianos/economia , Antiulcerosos/administração & dosagem , Antiulcerosos/economia , Claritromicina/administração & dosagem , Claritromicina/economia , Análise Custo-Benefício , Quimioterapia Combinada , Úlcera Duodenal/tratamento farmacológico , Úlcera Duodenal/economia , Humanos , Lansoprazol , Cadeias de Markov , Omeprazol/administração & dosagem , Omeprazol/economia , Penicilinas/administração & dosagem , Penicilinas/economia , Úlcera Gástrica/tratamento farmacológico , Úlcera Gástrica/economia , Resultado do Tratamento
4.
Nihon Eiseigaku Zasshi ; 49(2): 533-42, 1994 Jun.
Artigo em Japonês | MEDLINE | ID: mdl-8041010

RESUMO

The quality of life (QOL) in aged people is an important issue that has been discussed for a long time and led to a number of studies. In this review article, the relationship between subjective QOL of the aged and various factors is summarized by referring to articles published in the United States of America. In the first chapter, representative methods for the quantitative analysis of subjective QOL are described. Among a variety of methods for measuring subjective QOL, the LSI-A and the PGC Morale Scales are commonly used. In the next chapter, based on the studies using these methods, various factors that determined subjective QOL are analyzed. These studies indicate that physical well-being and socio-economic status are significant determinants of the QOL for the aged people. In addition, employment and social activity are shown to be associated with subjective QOL. On the other hand, age, gender, race and marital status do not have an influence on subjective QOL for the aged as individual factors. QOL can not be measured with a unidimensional scale. Therefore, it is necessary for the investigator to carefully choose an appropriate analytical method by understanding the characteristics of the research subject and the purpose of the study. It is also essential to keep it in mind that any method has its own limitations in analyzing QOL.


Assuntos
Idoso , Qualidade de Vida , Adulto , Humanos , Pessoa de Meia-Idade , Satisfação Pessoal
5.
Br J Cancer ; 97(11): 1493-8, 2007 Dec 03.
Artigo em Inglês | MEDLINE | ID: mdl-18040274

RESUMO

(18)F-2-deoxy-2-fluoro-glucose Positron Emission Tomography (FDG-PET) has been recently proposed as a promising cancer-screening test. However, the validity of FDG-PET in cancer screening has not been evaluated. We investigated the sensitivity of FDG-PET compared with upper gastric endoscopy in gastric cancer screening for asymptomatic individuals. A total of 2861 consecutive subjects (1600 men and 1261 women) who were asymptomatic and who underwent both FDG-PET and upper gastrointestinal endoscopy between 1 February 2004 and 31 January 2005 were included in this study. Both endoscopists and a radiologist were unaware of the results of the other diagnostic tests. The FDG-PET images were examined using criteria determined by the pattern of FDG accumulation. Sensitivity and specificity of FDG-PET were calculated compared with endoscopic diagnosis as the gold standard. Among 2861 subjects enrolled in the study, there were 20 subjects with gastric cancer, of whom 18 were T1 in depth of cancer invasion. Positive FDG-PET results were obtained only in 2 of the 20 cancer subjects. The calculated sensitivity and specificity for overall gastric cancers were 10.0% (95% confidence interval (CI): 1.2-31.7%) and 99.2% (95% CI: 98.8-99.5%), respectively. (18)F-2-deoxy-2-fluoro-glucose Positron Emission Tomography was poorly sensitive for detection of gastric cancer in the early stages.


Assuntos
Endoscopia Gastrointestinal/métodos , Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons/métodos , Neoplasias Gástricas/diagnóstico , Idoso , Feminino , Humanos , Masculino , Programas de Rastreamento/métodos , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
6.
Environ Health Prev Med ; 5(3): 111-7, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21432194

RESUMO

To determine the optimal strategy for prostate cancer screening, the cost-effectiveness of screening was analyzed using a medical decision model. One hundred thousand asymptomatic males between the ages of 40 and 69 were modeled with and without screening. The subjects were divided into three 10-year age groups. We used a 5-year survival rate as an effectiveness point and assumed after 5 year survival free from prostate cancer. We considered three potential programs: 1) screening with digital rectal examination (DRE), 2) screening with prostate specific antigen (PSA), and 3) screening with a combination of DRE and PSA. The study was analyzed from the payer's perspective, and only direct medical costs were included. For each of the three age groups, PSA screening was more cost-effective than either DRE screening or a combination of DRE and PSA screening. The cost-effectiveness ratio for the combination of DRE and PSA screening was 1.1-2.3 times more expensive dian that of PSA screening. If the compliance rate for work-up exams is 80%, the cost-effectiveness of prostate cancer screening is approximate to that of gastric cancer screening. In conclusion, PSA screening is the most cost-effective strategy for prostate cancer screening when compared with both DRE and the combination of DRE and PSA screening. But prostate cancer screening should be carefully conducted, taking the cost-effectiveness of the different strategies and target groups into consideration.

7.
Environ Health Prev Med ; 6(3): 189-91, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21432260

RESUMO

OBJECTIVE: Although the Japanese EuroQol instrument was developed in 1998 by a Japanese translation team, the reliability of health state valuations of the fuller questionnaire has not yet been investigated in Japan. We carried out a pilot study to investigate the reliability of health state valuations of the Japanese EuroQol instrument. METHODS: The survey was conducted twice with the fuller questionnaire of the Japanese EuroQol instrument in a class of preventive medicine. We analyzed test-retest reliability based on the health state valuations and calculated Cronbach's coefficient alpha of both tests. RESULTS AND CONCLUSIONS: The mean valuations of 14 hypothetical health states and 'death' between test and retest were not significantly different by paired t-test. The reliability by calculated correlation between test and retest was 0.996 (p<0.0001). In addition, Cronbach's coefficient alpha of the first test was 0.827, and that of the second test was 0.865. Although good reliability was shown in the present study, our conclusion was limited to applications of population-based surveys because of the small number and limited subjects of the present study. Further investigations are required in the form of a population-based survey.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA